XFOR
X4 Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.98
Current Price| Previous Close | $3.70 |
| Open | $3.66 |
| Day High | $4.00 |
| Day Low | $3.66 |
| Volume | 385,605 |
Stock Information
| Shares Outstanding | 87.44M |
| Total Debt | $77.36M |
| Cash Equivalents | $122.19M |
| Revenue | $33.98M |
| Net Income | $-95.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $348.00M |
| EPS (TTM) | $-8.92 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 9/42| Debt to Equity | 3.53 |
| Debt to Earnings | 44.37 |
| Current Ratio | 3.41 |
| Quick Ratio | 3.16 |
| Profit Margin | -1464.61% |
| Return on Equity | -169.08% |
| Avg FCF Growth | 23.32% |
| FCF Yield | -39.72% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.98 | 385,605 |
| 2026-01-30 | $3.70 | 255,500 |
| 2026-01-29 | $3.69 | 226,800 |
| 2026-01-28 | $3.62 | 204,000 |
| 2026-01-27 | $3.70 | 191,700 |
| 2026-01-26 | $3.63 | 255,100 |
| 2026-01-23 | $3.70 | 221,900 |
| 2026-01-22 | $3.76 | 354,700 |
| 2026-01-21 | $3.75 | 193,000 |
| 2026-01-20 | $3.67 | 327,700 |
| 2026-01-16 | $3.70 | 270,000 |
| 2026-01-15 | $3.62 | 548,600 |
| 2026-01-14 | $3.77 | 313,100 |
| 2026-01-13 | $3.87 | 338,500 |
| 2026-01-12 | $3.90 | 353,700 |
| 2026-01-09 | $4.00 | 1,089,000 |
| 2026-01-08 | $4.04 | 352,400 |
| 2026-01-07 | $4.00 | 422,100 |
| 2026-01-06 | $3.96 | 243,800 |
| 2026-01-05 | $3.84 | 269,500 |
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
đ° Latest News
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31%
Simply Wall St. âĸ 2026-01-18T13:05:06Z
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
Zacks âĸ 2026-01-12T17:00:03Z
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
Zacks âĸ 2025-12-24T14:55:02Z
Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves
Simply Wall St. âĸ 2025-12-08T11:04:59Z
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing
Simply Wall St. âĸ 2025-11-24T08:07:37Z
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks âĸ 2025-11-05T15:00:04Z
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-05T13:15:04Z
Techne (TECH) Meets Q1 Earnings Estimates
Zacks âĸ 2025-11-05T12:40:03Z
X4 Pharmaceuticals: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-05T12:22:35ZX4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks âĸ 2025-10-22T16:00:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $797,000 | $0 | $0 | - |
| Cost Of Revenue | $797,000 | $0 | $0 | - |
| Total Revenue | $2,557,000 | $0 | $0 | $0 |
| Operating Revenue | $2,557,000 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $8,768,000 | $5,777,000 | $3,993,000 | $3,642,000 |
| Total Expenses | $143,958,000 | $107,522,000 | $88,078,000 | $75,349,000 |
| Other Income Expense | $107,260,000 | $7,628,000 | $-1,987,000 | $-9,698,000 |
| Other Non Operating Income Expenses | $332,000 | $554,000 | $-4,197,000 | $426,000 |
| Net Non Operating Interest Income Expense | $-2,999,000 | $-1,195,000 | $-3,774,000 | $-3,632,000 |
| Interest Expense Non Operating | $8,768,000 | $5,777,000 | $3,993,000 | $3,642,000 |
| Operating Expense | $143,161,000 | $107,522,000 | $88,078,000 | $75,349,000 |
| General And Administrative Expense | - | - | - | $24,702,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Net Interest Income | $-2,999,000 | $-1,195,000 | $-3,774,000 | $-3,632,000 |
| Interest Income | $5,769,000 | $4,582,000 | $219,000 | $10,000 |
| Normalized Income | $-121,923,120 | $-106,755,460 | $-95,612,900 | $-81,305,480 |
| Net Income From Continuing And Discontinued Operation | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Total Operating Income As Reported | $-36,401,000 | $-107,522,000 | $-87,569,000 | $-85,107,000 |
| Net Income Common Stockholders | $-37,450,000 | $-101,167,000 | $-96,413,000 | $-102,639,000 |
| Net Income | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Net Income Including Noncontrolling Interests | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Net Income Continuous Operations | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Pretax Income | $-37,140,000 | $-101,089,000 | $-93,839,000 | $-88,679,000 |
| Special Income Charges | $105,000,000 | $0 | $509,000 | $-9,758,000 |
| Interest Income Non Operating | $5,769,000 | $4,582,000 | $219,000 | $10,000 |
| Operating Income | $-141,401,000 | $-107,522,000 | $-88,078,000 | $-75,349,000 |
| Gross Profit | $1,760,000 | $0 | $0 | - |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-5.70 | $-17.10 | $-45.60 | $-119.70 |
| Basic EPS | $-5.70 | $-17.10 | $-45.60 | $-119.70 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $22,454,880 | $1,485,540 | $464,100 | $-2,733,480 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-134,504,000 | $-101,967,000 | $-91,543,000 | $-74,414,000 |
| Total Unusual Items | $106,928,000 | $7,074,000 | $2,210,000 | $-10,124,000 |
| Total Unusual Items Excluding Goodwill | $106,928,000 | $7,074,000 | $2,210,000 | $-10,124,000 |
| Reconciled Depreciation | $796,000 | $419,000 | $513,000 | $499,000 |
| EBITDA (Bullshit earnings) | $-27,576,000 | $-94,893,000 | $-89,333,000 | $-84,538,000 |
| EBIT | $-28,372,000 | $-95,312,000 | $-89,846,000 | $-85,037,000 |
| Diluted Average Shares | $6,702,066 | $5,927,082 | $2,117,533 | $858,299 |
| Basic Average Shares | $6,702,066 | $5,927,082 | $2,117,533 | $858,299 |
| Diluted NI Availto Com Stockholders | $-37,450,000 | $-101,167,000 | $-96,413,000 | $-102,639,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $2,546,000 | $13,943,000 |
| Tax Provision | $310,000 | $78,000 | $28,000 | $17,000 |
| Gain On Sale Of Ppe | $105,000,000 | $0 | $509,000 | $0 |
| Gain On Sale Of Security | $1,928,000 | $7,074,000 | $1,701,000 | $-366,000 |
| Research And Development | $81,643,000 | $72,017,000 | $61,058,000 | $50,647,000 |
| Selling General And Administration | $61,518,000 | $35,505,000 | $27,020,000 | $24,702,000 |
| Impairment Of Capital Assets | - | $0 | $0 | $9,758,000 |
| Other Gand A | - | - | - | $24,702,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-5,202,000 | $33,748,000 | $56,700,000 | $47,061,000 |
| Total Assets | $146,447,000 | $147,258,000 | $155,586,000 | $117,176,000 |
| Total Non Current Assets | $34,272,000 | $25,182,000 | $26,909,000 | $29,298,000 |
| Other Non Current Assets | $2,080,000 | $1,436,000 | $1,225,000 | $1,723,000 |
| Goodwill And Other Intangible Assets | $27,351,000 | $17,351,000 | $17,351,000 | $17,351,000 |
| Other Intangible Assets | $10,000,000 | - | - | - |
| Current Assets | $112,175,000 | $122,076,000 | $128,677,000 | $87,878,000 |
| Other Current Assets | $5,588,000 | $7,298,000 | $5,807,000 | $5,344,000 |
| Inventory | $2,817,000 | $0 | - | - |
| Receivables | $1,710,000 | $562,000 | $1,152,000 | $747,000 |
| Other Receivables | $640,000 | $562,000 | $1,152,000 | $747,000 |
| Accounts Receivable | $1,070,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $102,060,000 | $114,216,000 | $121,718,000 | $81,787,000 |
| Cash And Cash Equivalents | $55,699,000 | $99,216,000 | $121,718,000 | $81,787,000 |
| Prepaid Assets | - | - | - | $5,344,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $19,726,000 | - | - | - |
| Total Debt | $78,086,000 | $58,281,000 | $38,420,000 | $39,785,000 |
| Long Term Debt And Capital Lease Obligation | $76,835,000 | $57,182,000 | $35,907,000 | $37,915,000 |
| Long Term Debt | $75,425,000 | $54,570,000 | $32,304,000 | $33,139,000 |
| Current Debt And Capital Lease Obligation | $1,251,000 | $1,099,000 | $2,513,000 | $1,870,000 |
| Current Debt | - | - | $1,315,000 | $795,000 |
| Other Current Borrowings | - | - | $1,315,000 | $795,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $124,298,000 | $96,159,000 | $81,535,000 | $52,764,000 |
| Total Non Current Liabilities Net Minority Interest | $91,421,000 | $73,297,000 | $59,211,000 | $38,741,000 |
| Other Non Current Liabilities | $831,000 | $432,000 | $173,000 | $826,000 |
| Derivative Product Liabilities | $13,755,000 | $15,683,000 | $23,131,000 | $0 |
| Current Liabilities | $32,877,000 | $22,862,000 | $22,324,000 | $14,023,000 |
| Payables And Accrued Expenses | $18,573,000 | $13,568,000 | $13,219,000 | $6,736,000 |
| Payables | $8,621,000 | $8,947,000 | $7,777,000 | $4,283,000 |
| Accounts Payable | $8,621,000 | $8,947,000 | $7,777,000 | $4,283,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $22,149,000 | $51,099,000 | $74,051,000 | $64,412,000 |
| Total Equity Gross Minority Interest | $22,149,000 | $51,099,000 | $74,051,000 | $64,412,000 |
| Stockholders Equity | $22,149,000 | $51,099,000 | $74,051,000 | $64,412,000 |
| Gains Losses Not Affecting Retained Earnings | $-122,000 | $-119,000 | $-119,000 | $-119,000 |
| Other Equity Adjustments | $-122,000 | $-119,000 | $-119,000 | $-119,000 |
| Retained Earnings | $-515,355,000 | $-477,905,000 | $-376,738,000 | $-282,871,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $5,698,231 | $5,581,153 | $4,055,574 | $937,588 |
| Share Issued | $5,698,231 | $5,581,153 | $4,055,574 | $937,588 |
| Tangible Book Value | $-5,202,000 | $33,748,000 | $56,700,000 | $47,061,000 |
| Invested Capital | $97,574,000 | $105,669,000 | $107,670,000 | $98,346,000 |
| Working Capital | $79,298,000 | $99,214,000 | $106,353,000 | $73,855,000 |
| Capital Lease Obligations | $2,661,000 | $3,711,000 | $4,801,000 | $5,851,000 |
| Total Capitalization | $97,574,000 | $105,669,000 | $106,355,000 | $97,551,000 |
| Additional Paid In Capital | $537,455,000 | $528,956,000 | $450,786,000 | $347,374,000 |
| Capital Stock | $171,000 | $167,000 | $122,000 | $28,000 |
| Common Stock | $171,000 | $167,000 | $122,000 | $28,000 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $1,410,000 | $2,612,000 | $3,603,000 | $4,776,000 |
| Current Capital Lease Obligation | $1,251,000 | $1,099,000 | $1,198,000 | $1,075,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,053,000 | $8,195,000 | $6,592,000 | $5,417,000 |
| Current Accrued Expenses | $9,952,000 | $4,621,000 | $5,442,000 | $2,453,000 |
| Goodwill | $17,351,000 | $17,351,000 | $17,351,000 | $17,351,000 |
| Net PPE | $4,841,000 | $6,395,000 | $8,333,000 | $10,224,000 |
| Accumulated Depreciation | $-1,903,000 | $-1,619,000 | $-1,228,000 | $-724,000 |
| Gross PPE | $6,744,000 | $8,014,000 | $9,561,000 | $10,948,000 |
| Leases | $228,000 | $228,000 | $228,000 | $228,000 |
| Other Properties | $4,734,000 | $6,301,000 | $7,868,000 | $9,286,000 |
| Machinery Furniture Equipment | $1,782,000 | $1,485,000 | $1,465,000 | $1,434,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $680,000 | $0 | - | - |
| Work In Process | $608,000 | $0 | - | - |
| Raw Materials | $1,529,000 | $0 | - | - |
| Other Short Term Investments | $46,361,000 | $15,000,000 | $0 | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-138,227,000 | $-96,572,000 | $-77,205,000 | $-71,520,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-130,901,000 | $-96,512,000 | $-77,102,000 | $-70,905,000 |
| Cash Flow From Continuing Operating Activities | $-130,901,000 | $-96,512,000 | $-77,102,000 | $-70,905,000 |
| Operating Gains Losses | $-106,928,000 | $-7,074,000 | $2,881,000 | $366,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-7,326,000 | $-60,000 | $-103,000 | $-615,000 |
| Investing Cash Flow | $66,990,000 | $-14,883,000 | $-103,000 | $-615,000 |
| Cash Flow From Continuing Investing Activities | $66,990,000 | $-14,883,000 | $-103,000 | $-615,000 |
| Net Other Investing Changes | $105,000,000 | - | - | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $59,999,000 | $122,631,000 | $75,985,000 |
| Financing Cash Flow | $20,294,000 | $88,516,000 | $117,230,000 | $74,245,000 |
| Cash Flow From Continuing Financing Activities | $20,294,000 | $88,516,000 | $117,230,000 | $74,245,000 |
| Net Common Stock Issuance | $0 | $59,999,000 | $122,631,000 | $73,985,000 |
| Common Stock Issuance | $0 | $59,999,000 | $122,631,000 | $75,985,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-2,000,000 |
| Net Other Financing Charges | - | $-631,000 | $-4,814,000 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $0 | $-2,064,000 | $-795,000 | $0 |
| Issuance Of Debt | $20,000,000 | $22,500,000 | $0 | $0 |
| Interest Paid Supplemental Data | $7,766,000 | $4,604,000 | $3,006,000 | $2,906,000 |
| End Cash Position | $56,475,000 | $100,248,000 | $123,028,000 | $83,108,000 |
| Beginning Cash Position | $100,248,000 | $123,028,000 | $83,108,000 | $80,702,000 |
| Effect Of Exchange Rate Changes | $-156,000 | $99,000 | $-105,000 | $-319,000 |
| Changes In Cash | $-43,617,000 | $-22,879,000 | $40,025,000 | $2,725,000 |
| Proceeds From Stock Option Exercised | $294,000 | $8,712,000 | $208,000 | $260,000 |
| Net Issuance Payments Of Debt | $20,000,000 | $20,436,000 | $-795,000 | $0 |
| Net Long Term Debt Issuance | $20,000,000 | $20,436,000 | $-795,000 | $0 |
| Long Term Debt Payments | $0 | $-2,064,000 | $-795,000 | $0 |
| Long Term Debt Issuance | $20,000,000 | $22,500,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-30,684,000 | $-14,823,000 | $0 | $0 |
| Sale Of Investment | $26,450,000 | $2,000,000 | $0 | $0 |
| Purchase Of Investment | $-57,134,000 | $-16,823,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-7,000,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-7,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-326,000 | $-60,000 | $-103,000 | $-615,000 |
| Purchase Of PPE | $-326,000 | $-60,000 | $-103,000 | $-615,000 |
| Change In Working Capital | $2,675,000 | $344,000 | $5,736,000 | $-1,498,000 |
| Change In Other Current Liabilities | $-1,004,000 | $-1,128,000 | $-882,000 | $-698,000 |
| Change In Payables And Accrued Expense | $6,883,000 | $2,842,000 | $7,228,000 | $1,014,000 |
| Change In Accrued Expense | $7,169,000 | $1,608,000 | $3,803,000 | $-152,000 |
| Change In Payable | $-286,000 | $1,234,000 | $3,425,000 | $1,166,000 |
| Change In Account Payable | $-286,000 | $1,234,000 | $3,425,000 | $1,166,000 |
| Change In Prepaid Assets | $683,000 | $-1,370,000 | $-610,000 | $-1,755,000 |
| Change In Inventory | $-2,817,000 | $0 | $0 | - |
| Change In Receivables | $-1,070,000 | $0 | $0 | - |
| Changes In Account Receivables | $-1,070,000 | $0 | $0 | - |
| Other Non Cash Items | $1,802,000 | $2,279,000 | $2,436,000 | $2,486,000 |
| Stock Based Compensation | $8,204,000 | $8,687,000 | $5,199,000 | $6,180,000 |
| Depreciation Amortization Depletion | $796,000 | $419,000 | $513,000 | $499,000 |
| Depreciation And Amortization | $796,000 | $419,000 | $513,000 | $499,000 |
| Gain Loss On Investment Securities | $-1,928,000 | $-7,074,000 | $2,881,000 | $366,000 |
| Net Income From Continuing Operations | $-37,450,000 | $-101,167,000 | $-93,867,000 | $-88,696,000 |
| Common Stock Payments | - | $0 | $0 | $-2,000,000 |
| Change In Other Current Assets | - | $0 | $0 | $-59,000 |
| Asset Impairment Charge | - | $0 | $0 | $9,758,000 |